3',4',3,5,7-pentamethoxy-4-thioflavone | 84212-84-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 3',4',3,5,7-pentamethoxy-4-thioflavone
• 英文别名: 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy-4H-chromene-4-thione；3,5,7,3',4'-Pentamethoxy-4-thioflavon；2-(3,4-dimethoxy-phenyl)-3,5,7-trimethoxy-chromene-4-thione；2-(3,4-Dimethoxyphenyl)-3,5,7-trimethoxychromene-4-thione；2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxychromene-4-thione
• CAS: 84212-84-0
• 化学式: C₂₀H₂₀O₆S
• 分子量: 388.441
• InChiKey: XHAKQQVJUQJJMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.87
• 重原子数：
  27.0
• 可旋转键数：
  6.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  59.29
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  3',4',3,5,7-pentamethoxy-4-thioflavone 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以55%的产率得到2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromene-4-thione
  参考文献：
  名称：

  新型合成的黄酮衍生物可为增强抗增殖活性所需的结构特征提供重要见解†

  摘要：

  随着许多癌症显示出对当前化学疗法的抗性，寻找新型抗癌药引起了极大的关注。天然类黄酮已被确认为此类计划的有用线索。然而，由于通常缺乏对最佳活性的结构要求的深入了解，因此在实现类黄酮作为抗增殖剂的全部潜力之前，需要进行进一步的研究。本文构建了一个包含76个甲氧基和羟基黄酮及其4-硫代类似物的宽泛文库，并建立了它们与乳腺癌细胞系MCF-7（ER + ve），MCF-7 /的抗增殖活性的结构-活性关系。探测了DX（ER + ve，抗蒽环类）和MDA-MB-231（ER -ve）。在该库中，有42种化合物是新颖的，所有化合物的收率都很高，纯度95％。最有前途的先导化合物，特别是新型羟基4-硫代黄酮美国国家癌症研究所（NCI）进一步评估了15f和16f对多种癌细胞系的抗增殖活性，并显示出显着的生长抑制特征（例如化合物15f：MCF-7（GI 50 = 0.18μM），T-47D（GI 50 = 0.03μM）和MDA-MB-468（GI

  DOI：

  10.1039/c6ra11041j
• 作为产物：
  描述：

  槲皮素 在 劳森试剂 、 potassium hydroxide 作用下， 以 甲苯 为溶剂， 反应 4.0h， 生成 3',4',3,5,7-pentamethoxy-4-thioflavone
  参考文献：
  名称：

  新型合成的黄酮衍生物可为增强抗增殖活性所需的结构特征提供重要见解†

  摘要：

  随着许多癌症显示出对当前化学疗法的抗性，寻找新型抗癌药引起了极大的关注。天然类黄酮已被确认为此类计划的有用线索。然而，由于通常缺乏对最佳活性的结构要求的深入了解，因此在实现类黄酮作为抗增殖剂的全部潜力之前，需要进行进一步的研究。本文构建了一个包含76个甲氧基和羟基黄酮及其4-硫代类似物的宽泛文库，并建立了它们与乳腺癌细胞系MCF-7（ER + ve），MCF-7 /的抗增殖活性的结构-活性关系。探测了DX（ER + ve，抗蒽环类）和MDA-MB-231（ER -ve）。在该库中，有42种化合物是新颖的，所有化合物的收率都很高，纯度95％。最有前途的先导化合物，特别是新型羟基4-硫代黄酮美国国家癌症研究所（NCI）进一步评估了15f和16f对多种癌细胞系的抗增殖活性，并显示出显着的生长抑制特征（例如化合物15f：MCF-7（GI 50 = 0.18μM），T-47D（GI 50 = 0.03μM）和MDA-MB-468（GI

  DOI：

  10.1039/c6ra11041j

文献信息

• Exploring quercetin and luteolin derivatives as antiangiogenic agents
  作者：Divyashree Ravishankar、Kimberly A. Watson、Samuel Y. Boateng、Rebecca J. Green、Francesca Greco、Helen M.I. Osborn

  DOI：10.1016/j.ejmech.2015.04.056

  日期：2015.6

  The formation of new blood vessels from the pre-existing vasculature (angiogenesis) is a crucial stage in cancer progression and, indeed, angiogenesis inhibitors are now used as anticancer agents, clinically. Here we have explored the potential of flavonoid derivatives as antiangiogenic agents. Specifically, we have synthesised methoxy and 4-thio derivatives of the natural flavones quercetin and luteolin, two of which (4-thio quercetin and 4-thio luteolin) had never been previously reported. Seven of these compounds showed significant (p < 0.05) antiangiogenic activity in an in vitro scratch assay. Their activity ranged from an 86% inhibition of the vascular endothelium growth factor (VEGF)-stimulated migration (observed for methoxyquercetin at 10 mu M and for luteolin at 1 mu M) to a 36% inhibition (for thiomethoxy quercetin at 10 mu M). Western blotting studies showed that most (4 out of 7) compounds inhibited phosphorylation of the VEGF receptor-2 (VEGFR2), suggesting that the antiangiogenic activity was due to an interference with the VEGF/VEGFR2 pathway. Molecular modelling studies looking at the affinity of our compounds towards VEGFR and/or VEGF confirmed this hypothesis, and indeed the compound with the highest antiangiogenic activity (methoxyquercetin) showed the highest affinity towards VEGFR and VEGF. As reports from others have suggested that structurally similar compounds can elicit biological responses via a non-specific, promiscuous membrane perturbation, potential interactions of the active compounds with a model lipid bilayer were assessed via DSC. Luteolin and its derivatives did not perturb the model membrane even at concentrations 10 times higher than the biologically active concentration and only subtle interactions were observed for quercetin and its derivatives. Finally, cytotoxicity assessment of these flavonoid derivatives against MCF-7 breast cancer cells demonstrated also a direct anticancer activity albeit at generally higher concentrations than those required for an antiangiogenic effect (10 fold higher for the methoxy analogues). Taken together these results show promise for flavonoid derivatives as antiangiogenic agents. (C) 2015 Elsevier Masson SAS. All rights reserved.
• Briggs, Malcolm T.; Duncan, Graham L. S.; Thornber, Craig W., Journal of Chemical Research, Miniprint, 1982, # 9, p. 2461 - 2487
  作者：Briggs, Malcolm T.、Duncan, Graham L. S.、Thornber, Craig W.

  DOI：——

  日期：——